PRINCETON, N.J. and CAMBRIDGE, Mass., June 1, 2025 /PRNewswire/ -- Taiho Oncology, Inc., and Cullinan Therapeutics, Inc., announced today the publication of positive results from the REZILIENT1 trial in the peer-reviewed Journal of Clinical Oncology (JCO). REZILIENT1 is a Phase 1/2,...
Read More Details
Finally We wish PressBee provided you with enough information of ( Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology )
Also on site :
- Authorities investigate after 8 injured in Colorado attack by man they say yelled ‘Free Palestine’
- Country Icon, 63, Cancels Show at Last Minute Amid Health Issues, Leaving Fans Irate
- Meta wants to replace its human workers with AI to review privacy and societal risks